Paediatric percutaneous nephrolithotomy (P-PCNL) reporting checklist
CONCLUSION: This practical tool can aid clinicians and researchers when undertaking and reviewing studies on paediatric PCNL. This is highly relevant given the current heterogeneity that exists as well as debate in best practice patterns.PMID:37987596 | DOI:10.2340/sju.v58.13392 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 21, 2023 Category: Urology & Nephrology Authors: Patrick Julieb ø-Jones Øyvind Ulvik Christian Beisland Bhaskar K Somani Source Type: research
Abandoning testing for asymptomatic microscopic haematuria in Sweden - a long-term follow-up
CONCLUSIONS: Based on open-source registry data, the new restrictive policy was not found to adversely affect the survival of patients with urinary bladder cancer in Sweden. These observations argue against a major negative impact of abandoning further work-up for patients with AMH and may be of use for other countries when revising guidelines. The reduced number of patients undergoing investigation may allow for increased focus and be a relief both for caregivers and the health budget.PMID:37987210 | DOI:10.2340/sju.v58.11142 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 21, 2023 Category: Urology & Nephrology Authors: Per-Uno Malmstr öm G årdmark Truls Source Type: research
Paediatric percutaneous nephrolithotomy (P-PCNL) reporting checklist
CONCLUSION: This practical tool can aid clinicians and researchers when undertaking and reviewing studies on paediatric PCNL. This is highly relevant given the current heterogeneity that exists as well as debate in best practice patterns.PMID:37987596 | DOI:10.2340/sju.v58.13392 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 21, 2023 Category: Urology & Nephrology Authors: Patrick Julieb ø-Jones Øyvind Ulvik Christian Beisland Bhaskar K Somani Source Type: research
Abandoning testing for asymptomatic microscopic haematuria in Sweden - a long-term follow-up
CONCLUSIONS: Based on open-source registry data, the new restrictive policy was not found to adversely affect the survival of patients with urinary bladder cancer in Sweden. These observations argue against a major negative impact of abandoning further work-up for patients with AMH and may be of use for other countries when revising guidelines. The reduced number of patients undergoing investigation may allow for increased focus and be a relief both for caregivers and the health budget.PMID:37987210 | DOI:10.2340/sju.v58.11142 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 21, 2023 Category: Urology & Nephrology Authors: Per-Uno Malmstr öm G årdmark Truls Source Type: research
Paediatric percutaneous nephrolithotomy (P-PCNL) reporting checklist
CONCLUSION: This practical tool can aid clinicians and researchers when undertaking and reviewing studies on paediatric PCNL. This is highly relevant given the current heterogeneity that exists as well as debate in best practice patterns.PMID:37987596 | DOI:10.2340/sju.v58.13392 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 21, 2023 Category: Urology & Nephrology Authors: Patrick Julieb ø-Jones Øyvind Ulvik Christian Beisland Bhaskar K Somani Source Type: research
Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Conclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.PMID:37953521 | DOI:10.2340/sju.v58.5923 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Christina Tanem M øller Gunnar Tafjord Augun Blindheim Viktor Berge Sophie Foss å Bettina Kulle Andreassen Source Type: research
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden
CONCLUSIONS: Slightly more than half of men diagnosed with de novo metastatic castration-sensitive prostate cancer and a life expectancy of at least 3 years received additions to standard ADT as recommended by national guidelines in 2019-2022 in Sweden. There was a 2-fold increase in use of these treatments during the study period; however, efforts to further increase adherence to guidelines are warranted.PMID:37953522 | DOI:10.2340/sju.v58.9572 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Rolf Gedeborg Fredrik Sandin Camilla Thellenberg-Karlsson Johan Styrke Ingela Franck Lissbrant Hans Garmo P är Stattin Source Type: research
Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Conclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.PMID:37953521 | DOI:10.2340/sju.v58.5923 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Christina Tanem M øller Gunnar Tafjord Augun Blindheim Viktor Berge Sophie Foss å Bettina Kulle Andreassen Source Type: research
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden
CONCLUSIONS: Slightly more than half of men diagnosed with de novo metastatic castration-sensitive prostate cancer and a life expectancy of at least 3 years received additions to standard ADT as recommended by national guidelines in 2019-2022 in Sweden. There was a 2-fold increase in use of these treatments during the study period; however, efforts to further increase adherence to guidelines are warranted.PMID:37953522 | DOI:10.2340/sju.v58.9572 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Rolf Gedeborg Fredrik Sandin Camilla Thellenberg-Karlsson Johan Styrke Ingela Franck Lissbrant Hans Garmo P är Stattin Source Type: research
Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Conclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.PMID:37953521 | DOI:10.2340/sju.v58.5923 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Christina Tanem M øller Gunnar Tafjord Augun Blindheim Viktor Berge Sophie Foss å Bettina Kulle Andreassen Source Type: research
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden
CONCLUSIONS: Slightly more than half of men diagnosed with de novo metastatic castration-sensitive prostate cancer and a life expectancy of at least 3 years received additions to standard ADT as recommended by national guidelines in 2019-2022 in Sweden. There was a 2-fold increase in use of these treatments during the study period; however, efforts to further increase adherence to guidelines are warranted.PMID:37953522 | DOI:10.2340/sju.v58.9572 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Rolf Gedeborg Fredrik Sandin Camilla Thellenberg-Karlsson Johan Styrke Ingela Franck Lissbrant Hans Garmo P är Stattin Source Type: research
Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Conclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.PMID:37953521 | DOI:10.2340/sju.v58.5923 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Christina Tanem M øller Gunnar Tafjord Augun Blindheim Viktor Berge Sophie Foss å Bettina Kulle Andreassen Source Type: research
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden
CONCLUSIONS: Slightly more than half of men diagnosed with de novo metastatic castration-sensitive prostate cancer and a life expectancy of at least 3 years received additions to standard ADT as recommended by national guidelines in 2019-2022 in Sweden. There was a 2-fold increase in use of these treatments during the study period; however, efforts to further increase adherence to guidelines are warranted.PMID:37953522 | DOI:10.2340/sju.v58.9572 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Rolf Gedeborg Fredrik Sandin Camilla Thellenberg-Karlsson Johan Styrke Ingela Franck Lissbrant Hans Garmo P är Stattin Source Type: research
Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Conclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.PMID:37953521 | DOI:10.2340/sju.v58.5923 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Christina Tanem M øller Gunnar Tafjord Augun Blindheim Viktor Berge Sophie Foss å Bettina Kulle Andreassen Source Type: research
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden
CONCLUSIONS: Slightly more than half of men diagnosed with de novo metastatic castration-sensitive prostate cancer and a life expectancy of at least 3 years received additions to standard ADT as recommended by national guidelines in 2019-2022 in Sweden. There was a 2-fold increase in use of these treatments during the study period; however, efforts to further increase adherence to guidelines are warranted.PMID:37953522 | DOI:10.2340/sju.v58.9572 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Rolf Gedeborg Fredrik Sandin Camilla Thellenberg-Karlsson Johan Styrke Ingela Franck Lissbrant Hans Garmo P är Stattin Source Type: research
